<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908490</url>
  </required_header>
  <id_info>
    <org_study_id>PRO14120209</org_study_id>
    <nct_id>NCT02908490</nct_id>
  </id_info>
  <brief_title>Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?</brief_title>
  <official_title>Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kimberly Liang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sildenafil improves parameters of vascular&#xD;
      function and blood markers involved in development of heart disease in patients with&#xD;
      rheumatoid arthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis (RA) is associated with a 2-fold increased risk of cardiovascular&#xD;
      disease (CVD), which is not explained by traditional cardiovascular (CV) risk factors alone;&#xD;
      this risk is likely mediated in part through systemic inflammation. Indeed, RA itself is&#xD;
      deemed to impart a CV risk equivalent to diabetes mellitus (DM). However, unlike in DM,&#xD;
      optimal CV management strategies in RA are lacking. Despite improved anti-inflammatory&#xD;
      therapies for RA, the mortality gap in RA compared to the general population is still&#xD;
      widening, in part due to suboptimal primary and secondary CV preventive care in RA. To date,&#xD;
      there have been no published controlled intervention trials for primary CV prevention in RA,&#xD;
      despite this clearly urgent unmet need.&#xD;
&#xD;
      One of the early stages of atherogenesis is endothelial dysfunction, and drugs that target&#xD;
      improvement in this are promising novel strategies for CVD prevention. The fundamental&#xD;
      feature of endothelial dysfunction is impaired nitric oxide (NO) bioavailability. Sildenafil&#xD;
      improves endothelial function by increasing NO signaling by inhibition of phosphodiesterase-5&#xD;
      (PDE5). PDE5 inhibitors improve endothelial function in pulmonary hypertension and DM, and&#xD;
      were safe and well tolerated in patients with erectile dysfunction and other CV&#xD;
      comorbidities. Furthermore, PDE inhibitors have immunomodulatory properties that may be&#xD;
      utilized to treat autoimmune conditions like RA. The investigators' central hypothesis is&#xD;
      that sildenafil is a uniquely suited agent targeting endothelial dysfunction as a novel&#xD;
      adjunctive CV prevention strategy and immunomodulatory agent in RA. Specifically, their goal&#xD;
      is to determine if sildenafil use in RA improves endothelial dysfunction and atherosclerosis&#xD;
      biomarkers.&#xD;
&#xD;
      The proposed study is a phase II, randomized double-blind placebo-controlled crossover&#xD;
      efficacy trial of 60 RA patients, with no known history of CVD but at least one traditional&#xD;
      CV risk factor, on stable baseline doses of RA medications; randomized 1:1 to receive either&#xD;
      sildenafil 50 mg or placebo orally once daily for 3 months, with a 2-week washout before the&#xD;
      crossover phase for another 3 months. Vascular studies validated in assessing endothelial&#xD;
      dysfunction and laboratory studies for selected atherosclerosis biomarkers will be performed&#xD;
      at baseline, 3 months pre- and post-washout, and 6 months. Adverse events will be collected&#xD;
      to assess safety. The Specific Aims are:&#xD;
&#xD;
        1. To determine whether sildenafil use in RA leads to improvement in parameters of vascular&#xD;
           function; and to confirm its safety profile.&#xD;
&#xD;
        2. To determine whether sildenafil use in RA is associated with improvement in&#xD;
           atherosclerosis biomarkers.&#xD;
&#xD;
      The results of this study will serve as preliminary data for future larger trials evaluating&#xD;
      sildenafil as a CV prevention strategy by reducing endothelial dysfunction in RA. It will&#xD;
      provide needed data on potential benefits of sildenafil for immunomodulation and CV&#xD;
      prevention in this high-risk population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment, lack of continued funding&#xD;
  </why_stopped>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">June 4, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Brachial Artery Flow Mediated Dilation (FMD) Without Nitroglycerin at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>The methods of assessment of endothelial function via FMD will be performed following guidelines. Using Duplex ultrasound with a high-resolution linear array transducer, the difference between the maximum brachial artery diameter (BAD) postocclusion and the baseline diameter will be calculated, expressed as a percentage (%BAD). Generally, %BAD values below 5-7% represent endothelial dysfunction, which is associated with CV risk factors, future CVD and mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peripheral Arterial Tone (PAT) LnRHI at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>PAT measured by the EndoPAT 2000 device is a non-invasive method to assess endothelial function. It is a standardized, rapid, and easy to apply method, and has been found to correlate with multiple traditional CV risk factors and to be responsive to interventions. PAT is a validated alternative measure to brachial arterial FMD in assessing endothelial function, and is less operator-dependent than FMD. FMD directly measures the dilation capability of the large-conduit artery, whereas PAT measures flow response hyperemia, which is related to endothelial function of small arteries of microcirculation. PAT measures endothelium-mediated changes in vascular tone using bio-sensors placed on fingertips. The semi-automatically calculated result (Reactive Hyperemia Index) is an index of endothelial function. LnRHI is a Reactive Hyperemia Index after natural log transformation with a matched cutoff: Normal: LnRHI &gt; 0.51 and Abnormal: LnRHI &lt;= 0.51 cut-off.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>High-sensitivity CRP (hsCRP) measured using standard clinical laboratory protocols</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ESR at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>Erythrocyte sedimentation rate (ESR) measured using standard clinical laboratory protocols</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Participants With Detectable IL-6 at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>Interleukin (IL)-6 measured using enzyme linked immunosorbent assay (ELISA) (pg/mL). Since very few subjects had detectable IL-6 levels, the outcome measure reports the number of participants with detectable IL-6 rather than mean levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in RF at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>Rheumatoid factor (RF) measured using standard clinical laboratory protocols</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CCP at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>Anti-cyclic citrullinated peptide antibody (CCP) measured using standard clinical laboratory protocols. Note, the universal unit of measure for CCP is &quot;Units.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in E-selectin at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>Leukocyte adhesion molecule E-selectin measured using enzyme linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ICAM-1 at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>Intercellular adhesion molecule (ICAM)-1 measured using enzyme linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in VCAM-1 at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>Vascular cell adhesion molecule (VCAM)-1 measured using enzyme linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD40L at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>CD40 ligand (CD40L) measured using enzyme linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MMP-9 at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>Matrix metalloproteinase-9 (MMP-9) measured using enzyme linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MPO at 3 Months</measure>
    <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
    <description>Myeloperoxidase (MPO) measured using enzyme linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAE)</measure>
    <time_frame>6 Months and 2 Weeks from Baseline Visit</time_frame>
    <description>SAEs include death, hospitalization or prolonged existing hospitalization, life threatening, persistent or significant disability, birth defect/congenital anomaly, or medically significant event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AE) Related to Treatment</measure>
    <time_frame>6 Months and 2 Weeks from Baseline Visit</time_frame>
    <description>AEs related to sildenafil treatment may include headache, flushing, indigestion, or visual disturbance, among others.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Initial Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initial Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil 50 mg once daily</description>
    <arm_group_label>Initial Placebo</arm_group_label>
    <arm_group_label>Initial Sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
    <other_name>Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill</description>
    <arm_group_label>Initial Placebo</arm_group_label>
    <arm_group_label>Initial Sildenafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets 2010 American College of Rheumatology (ACR) classification criteria for&#xD;
             diagnosis of RA&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  No known history of CVD (see Exclusion Criteria)&#xD;
&#xD;
          -  At least one traditional CV risk factor (i.e., older age [men ≥45 years, women ≥55&#xD;
             years], obesity [defined as body mass index (BMI) &gt;30 kg/m2], smoking, hypertension,&#xD;
             hyperlipidemia, diabetes mellitus, family history of premature [defined as diagnosed&#xD;
             at &lt;65 years old] CVD in first-degree relative)&#xD;
&#xD;
          -  On stable baseline doses of RA medications, defined as no change in dose within past 4&#xD;
             weeks and no anticipated changes over the next 6 months&#xD;
&#xD;
          -  On no higher than 10 mg per day of prednisone or prednisone-equivalent within past 4&#xD;
             weeks&#xD;
&#xD;
          -  RA disease duration (from symptom onset) of more than 6 months&#xD;
&#xD;
          -  Having clinical disease activity index (CDAI) of &gt;2.8 but ≤22 (i.e., either low or&#xD;
             moderate disease activity), within 30 days of study enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Aged &lt;18 years&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Known personal history of CVD (clinical diagnoses of stroke, transient ischemic&#xD;
             attack, myocardial infarction, acute coronary syndrome, peripheral arterial disease,&#xD;
             percutaneous coronary intervention or coronary bypass graft surgery)&#xD;
&#xD;
          -  Use of high-dose statins (e.g., atorvastatin 40-80 mg/day or rosuvastatin 20-40&#xD;
             mg/day) currently or within past 3 months, or any dose changes of statins or of blood&#xD;
             pressure medications that may affect endothelial function (i.e.,&#xD;
             angiotensin-converting-enzyme [ACE] inhibitors or angiotensin receptor blockers&#xD;
             [ARBs]) within past 3 months. If on statin or an ACE-I or ARB, there should be no&#xD;
             anticipated dose changes over the next 6 months.&#xD;
&#xD;
          -  Persons with intra-cardiac and intra-pulmonary shunts, unstable cardiopulmonary&#xD;
             conditions, or anyone on chronic oxygen therapy&#xD;
&#xD;
          -  Persons taking nitric oxide donors, organic nitrites and nitrates, such as glyceryl&#xD;
             trinitrate (nitroglycerin), sodium nitroprusside, amyl nitrite (&quot;poppers&quot;)&#xD;
&#xD;
          -  Severe hepatic impairment (liver function tests &gt;1.5 times upper limit of normal)&#xD;
             within past 4 weeks&#xD;
&#xD;
          -  Severe impairment in renal function (serum creatinine ≥1.5 mg/dL) within past 4 weeks&#xD;
&#xD;
          -  Hypotension (defined as blood pressure [BP] &lt;90/60)&#xD;
&#xD;
          -  Hereditary degenerative retinal disorders (including genetic disorders of retinal&#xD;
             phosphodiesterases)&#xD;
&#xD;
          -  Persons already taking (or taken within 3 months) sildenafil or other PDE inhibitors&#xD;
             (i.e., tadalafil, vardenafil)&#xD;
&#xD;
          -  Persons unable to provide voluntary written informed consent&#xD;
&#xD;
          -  Severe hypertension (BP &gt;170/110)&#xD;
&#xD;
          -  Persons with HIV/AIDS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly P Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <results_first_submitted>May 31, 2021</results_first_submitted>
  <results_first_submitted_qc>July 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2021</results_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Kimberly Liang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Arthritis, Rheumatoid</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02908490/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Initial Sildenafil</title>
          <description>Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months&#xD;
Sildenafil: Sildenafil 50 mg once daily&#xD;
Placebo: Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill</description>
        </group>
        <group group_id="P2">
          <title>Initial Placebo</title>
          <description>Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months&#xD;
Sildenafil: Sildenafil 50 mg once daily&#xD;
Placebo: Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Initial Sildenafil</title>
          <description>Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months&#xD;
Sildenafil: Sildenafil 50 mg once daily&#xD;
Placebo: Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill</description>
        </group>
        <group group_id="B2">
          <title>Initial Placebo</title>
          <description>Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months&#xD;
Sildenafil: Sildenafil 50 mg once daily&#xD;
Placebo: Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.1" spread="11.2"/>
                    <measurement group_id="B2" value="62.9" spread="11.1"/>
                    <measurement group_id="B3" value="62.0" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiovascular Risk Factors</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Older age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obesity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking (ever or current)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family history of CVD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estrogen replacement use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Brachial Artery Flow Mediated Dilation (FMD) Without Nitroglycerin at 3 Months</title>
        <description>The methods of assessment of endothelial function via FMD will be performed following guidelines. Using Duplex ultrasound with a high-resolution linear array transducer, the difference between the maximum brachial artery diameter (BAD) postocclusion and the baseline diameter will be calculated, expressed as a percentage (%BAD). Generally, %BAD values below 5-7% represent endothelial dysfunction, which is associated with CV risk factors, future CVD and mortality.</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brachial Artery Flow Mediated Dilation (FMD) Without Nitroglycerin at 3 Months</title>
          <description>The methods of assessment of endothelial function via FMD will be performed following guidelines. Using Duplex ultrasound with a high-resolution linear array transducer, the difference between the maximum brachial artery diameter (BAD) postocclusion and the baseline diameter will be calculated, expressed as a percentage (%BAD). Generally, %BAD values below 5-7% represent endothelial dysfunction, which is associated with CV risk factors, future CVD and mortality.</description>
          <population>The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>percent of BAD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FMD at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" spread="4.05"/>
                    <measurement group_id="O2" value="6.48" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in FMD from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="4.72"/>
                    <measurement group_id="O2" value="0.814" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Given the cross-over design, analyses included a random effects model for within-subject comparisons of sildenafil versus placebo periods, adjusting for the baseline FMD within that period and a term for treatment order.</non_inferiority_desc>
            <p_value>0.185</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>-1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.54</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peripheral Arterial Tone (PAT) LnRHI at 3 Months</title>
        <description>PAT measured by the EndoPAT 2000 device is a non-invasive method to assess endothelial function. It is a standardized, rapid, and easy to apply method, and has been found to correlate with multiple traditional CV risk factors and to be responsive to interventions. PAT is a validated alternative measure to brachial arterial FMD in assessing endothelial function, and is less operator-dependent than FMD. FMD directly measures the dilation capability of the large-conduit artery, whereas PAT measures flow response hyperemia, which is related to endothelial function of small arteries of microcirculation. PAT measures endothelium-mediated changes in vascular tone using bio-sensors placed on fingertips. The semi-automatically calculated result (Reactive Hyperemia Index) is an index of endothelial function. LnRHI is a Reactive Hyperemia Index after natural log transformation with a matched cutoff: Normal: LnRHI &gt; 0.51 and Abnormal: LnRHI &lt;= 0.51 cut-off.</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peripheral Arterial Tone (PAT) LnRHI at 3 Months</title>
          <description>PAT measured by the EndoPAT 2000 device is a non-invasive method to assess endothelial function. It is a standardized, rapid, and easy to apply method, and has been found to correlate with multiple traditional CV risk factors and to be responsive to interventions. PAT is a validated alternative measure to brachial arterial FMD in assessing endothelial function, and is less operator-dependent than FMD. FMD directly measures the dilation capability of the large-conduit artery, whereas PAT measures flow response hyperemia, which is related to endothelial function of small arteries of microcirculation. PAT measures endothelium-mediated changes in vascular tone using bio-sensors placed on fingertips. The semi-automatically calculated result (Reactive Hyperemia Index) is an index of endothelial function. LnRHI is a Reactive Hyperemia Index after natural log transformation with a matched cutoff: Normal: LnRHI &gt; 0.51 and Abnormal: LnRHI &lt;= 0.51 cut-off.</description>
          <population>The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>LnRHI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LnRHI at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.29"/>
                    <measurement group_id="O2" value="0.78" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in LnRHI from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.54"/>
                    <measurement group_id="O2" value="-0.01" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Given the cross-over design, analyses included a random effects model for within-subject comparisons of sildenafil versus placebo periods, adjusting for the baseline EndoPAT within that period and a term for treatment order.</non_inferiority_desc>
            <p_value>0.003</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>0.200</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.069</ci_lower_limit>
            <ci_upper_limit>0.331</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP at 3 Months</title>
        <description>High-sensitivity CRP (hsCRP) measured using standard clinical laboratory protocols</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP at 3 Months</title>
          <description>High-sensitivity CRP (hsCRP) measured using standard clinical laboratory protocols</description>
          <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hsCRP at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.43"/>
                    <measurement group_id="O2" value="0.58" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in hsCRP from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.42"/>
                    <measurement group_id="O2" value="0.43" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ESR at 3 Months</title>
        <description>Erythrocyte sedimentation rate (ESR) measured using standard clinical laboratory protocols</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ESR at 3 Months</title>
          <description>Erythrocyte sedimentation rate (ESR) measured using standard clinical laboratory protocols</description>
          <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ESR at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.22" spread="15.64"/>
                    <measurement group_id="O2" value="17.35" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in ESR from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="5.73"/>
                    <measurement group_id="O2" value="3.95" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Participants With Detectable IL-6 at 3 Months</title>
        <description>Interleukin (IL)-6 measured using enzyme linked immunosorbent assay (ELISA) (pg/mL). Since very few subjects had detectable IL-6 levels, the outcome measure reports the number of participants with detectable IL-6 rather than mean levels.</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Participants With Detectable IL-6 at 3 Months</title>
          <description>Interleukin (IL)-6 measured using enzyme linked immunosorbent assay (ELISA) (pg/mL). Since very few subjects had detectable IL-6 levels, the outcome measure reports the number of participants with detectable IL-6 rather than mean levels.</description>
          <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number (%) of Participants with Detectable IL-6 at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change (decrease) in Number (%) of Participants with Detectable IL-6 from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in RF at 3 Months</title>
        <description>Rheumatoid factor (RF) measured using standard clinical laboratory protocols</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in RF at 3 Months</title>
          <description>Rheumatoid factor (RF) measured using standard clinical laboratory protocols</description>
          <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>IU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RF at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.17" spread="337.02"/>
                    <measurement group_id="O2" value="138.96" spread="296.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in RF from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" spread="81.29"/>
                    <measurement group_id="O2" value="-16.20" spread="59.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CCP at 3 Months</title>
        <description>Anti-cyclic citrullinated peptide antibody (CCP) measured using standard clinical laboratory protocols. Note, the universal unit of measure for CCP is &quot;Units.&quot;</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CCP at 3 Months</title>
          <description>Anti-cyclic citrullinated peptide antibody (CCP) measured using standard clinical laboratory protocols. Note, the universal unit of measure for CCP is &quot;Units.&quot;</description>
          <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CCP at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" spread="107.17"/>
                    <measurement group_id="O2" value="62.80" spread="105.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CCP from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.70" spread="38.93"/>
                    <measurement group_id="O2" value="-10.70" spread="32.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in E-selectin at 3 Months</title>
        <description>Leukocyte adhesion molecule E-selectin measured using enzyme linked immunosorbent assay (ELISA)</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in E-selectin at 3 Months</title>
          <description>Leukocyte adhesion molecule E-selectin measured using enzyme linked immunosorbent assay (ELISA)</description>
          <population>The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>E-Selectin at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.10" spread="14.68"/>
                    <measurement group_id="O2" value="42.56" spread="14.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in E-Selectin from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.91" spread="13.37"/>
                    <measurement group_id="O2" value="-2.56" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Given the cross-over design, analyses included a random effects model for within-subject comparisons of sildenafil versus placebo periods, adjusting for the baseline biomarker within that period and a term for treatment order.</non_inferiority_desc>
            <p_value>0.061</p_value>
            <p_value_desc>The a prior threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>7.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>15.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ICAM-1 at 3 Months</title>
        <description>Intercellular adhesion molecule (ICAM)-1 measured using enzyme linked immunosorbent assay (ELISA)</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ICAM-1 at 3 Months</title>
          <description>Intercellular adhesion molecule (ICAM)-1 measured using enzyme linked immunosorbent assay (ELISA)</description>
          <population>The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ICAM-1 at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.23" spread="65.96"/>
                    <measurement group_id="O2" value="299.59" spread="81.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in ICAM-1 from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.31" spread="77.03"/>
                    <measurement group_id="O2" value="-44.33" spread="67.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Given the cross-over design, analyses included a random effects model for within-subject comparisons of sildenafil versus placebo periods, adjusting for the baseline biomarker within that period and a term for treatment order.</non_inferiority_desc>
            <p_value>0.011</p_value>
            <p_value_desc>The a prior threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>55.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.79</ci_lower_limit>
            <ci_upper_limit>97.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in VCAM-1 at 3 Months</title>
        <description>Vascular cell adhesion molecule (VCAM)-1 measured using enzyme linked immunosorbent assay (ELISA)</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in VCAM-1 at 3 Months</title>
          <description>Vascular cell adhesion molecule (VCAM)-1 measured using enzyme linked immunosorbent assay (ELISA)</description>
          <population>The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VCAM-1 at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="751.30" spread="294.35"/>
                    <measurement group_id="O2" value="771.86" spread="231.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in VCAM-1 from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.12" spread="117.2"/>
                    <measurement group_id="O2" value="-33.23" spread="123.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Given the cross-over design, analyses included a random effects model for within-subject comparisons of sildenafil versus placebo periods, adjusting for the baseline biomarker within that period and a term for treatment order.</non_inferiority_desc>
            <p_value>0.077</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>74.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.98</ci_lower_limit>
            <ci_upper_limit>157.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD40L at 3 Months</title>
        <description>CD40 ligand (CD40L) measured using enzyme linked immunosorbent assay (ELISA)</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD40L at 3 Months</title>
          <description>CD40 ligand (CD40L) measured using enzyme linked immunosorbent assay (ELISA)</description>
          <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7650.22" spread="6994.27"/>
                    <measurement group_id="O2" value="10316.24" spread="8513.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CD40L from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2559.09" spread="9936.68"/>
                    <measurement group_id="O2" value="-3857.02" spread="6972.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MMP-9 at 3 Months</title>
        <description>Matrix metalloproteinase-9 (MMP-9) measured using enzyme linked immunosorbent assay (ELISA)</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MMP-9 at 3 Months</title>
          <description>Matrix metalloproteinase-9 (MMP-9) measured using enzyme linked immunosorbent assay (ELISA)</description>
          <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMP-9 at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441.00" spread="399.32"/>
                    <measurement group_id="O2" value="454.85" spread="298.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in MMP-9 from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.61" spread="437.21"/>
                    <measurement group_id="O2" value="-105.65" spread="333.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MPO at 3 Months</title>
        <description>Myeloperoxidase (MPO) measured using enzyme linked immunosorbent assay (ELISA)</description>
        <time_frame>Baseline and After 3 months of Study Drug use (i.e., either at 3 months pre-washout or at 6 months, depending on group assignment)</time_frame>
        <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MPO at 3 Months</title>
          <description>Myeloperoxidase (MPO) measured using enzyme linked immunosorbent assay (ELISA)</description>
          <population>Pre-specified linear mixed model statistical analysis not conducted because not scientifically appropriate due to insufficient enrollment.&#xD;
The number of participants analyzed reflects those in each period who had evaluable data for the given outcome measure at both the Baseline and After 3 months of Study Drug use timepoints.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MPO at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.68" spread="276.33"/>
                    <measurement group_id="O2" value="233.24" spread="241.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in MPO from Baseline at 3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.18" spread="242.20"/>
                    <measurement group_id="O2" value="-54.04" spread="309.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events (SAE)</title>
        <description>SAEs include death, hospitalization or prolonged existing hospitalization, life threatening, persistent or significant disability, birth defect/congenital anomaly, or medically significant event.</description>
        <time_frame>6 Months and 2 Weeks from Baseline Visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events (SAE)</title>
          <description>SAEs include death, hospitalization or prolonged existing hospitalization, life threatening, persistent or significant disability, birth defect/congenital anomaly, or medically significant event.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (AE) Related to Treatment</title>
        <description>AEs related to sildenafil treatment may include headache, flushing, indigestion, or visual disturbance, among others.</description>
        <time_frame>6 Months and 2 Weeks from Baseline Visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil Period</title>
            <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo Period</title>
            <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AE) Related to Treatment</title>
          <description>AEs related to sildenafil treatment may include headache, flushing, indigestion, or visual disturbance, among others.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over the entire study duration for each participant (i.e., 6 months and 2 weeks).</time_frame>
      <desc>The definition of adverse event and/or serious adverse event did not differ from the clinicaltrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sildenafil Period</title>
          <description>Participants who received Sildenafil 50 mg once daily in either the first or last 3 months of the study</description>
        </group>
        <group group_id="E2">
          <title>Placebo Period</title>
          <description>Participants who received Placebo tablets (matching Sildenafil 50 mg) once daily in either the first or last 3 months of the study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly P. Liang, MD, MS</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-586-3550</phone>
      <email>liangkp@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

